Arvin Iracheta-Vellve

Oct 4, 2023 | nature.com | Christina Baumgartner |Arvin Iracheta-Vellve |Kira E. Olander |Omar Ávila |Audrey J. Muscato |James C. Patti | +13 more

AbstractImmune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2. The protein tyrosine phosphatases PTPN2 and PTPN1 are central regulators of inflammation, and their genetic deletion in either tumour cells or immune cells promotes anti-tumour immunity3,4,5,6. However, phosphatases are challenging drug targets; in particular, the active site has been considered undruggable.